| Dr Ezechinyerem D Uzosike, MD | |
|
2050 Pfingsten Rd, Suite 200, Glenview, IL 60026-1324 | |
| (847) 657-1840 | |
| (847) 657-1823 |
| Full Name | Dr Ezechinyerem D Uzosike |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 13 Years |
| Location | 2050 Pfingsten Rd, Glenview, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063703064 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 125061451 (Illinois) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Permanente Medical Group Inc | 8921910225 | 7800 |
News Archive
Bionomics Limited announced today the publication of its international clinical study involving patients with a form of epilepsy confined to early childhood in the scientific journal, Annals of Neurology. The publication details genes associated with a condition known as Benign Familial Neonatal Infantile Spasms (BFNIS), a condition in which infants experience seizures in the first few months of their life.
Some prostate cancer patients unnecessarily undergo surgery or harsh treatments because science fails to identify the differences between slow-growing and aggressive forms of the disease. Researchers at Case Western Reserve University and Johns Hopkins Medical Institutes are developing technology that allows patients to safely choose to do nothing, opt for relatively mild treatments or take drastic measures.
The twin epidemics of obesity and type 2 diabetes will continue to fuel an explosion in heart failure, already the world's most prevalent chronic cardiovascular disease, according to John McMurray, professor of cardiology at the Western Infirmary, Glasgow, and President of the Heart Failure Association. He reported that around one-third of patients with heart failure have evidence of diabetes, and for them the outlook is very serious. For doctors, he added, effective treatment is "very difficult".
Matrix-Bio, Inc., a diagnostics company that uses metabolite profiling to detect cancer and other diseases, has signed an exclusive global licensing and marketing agreement for metabolomic biomarkers with Quest Diagnostics, the world's leading provider of diagnostic information services. Under the agreement, Quest Diagnostics will have the rights to use the biomarkers for the future, potential development of a clinical lab-developed test to aid in the detection of breast cancer recurrence.
› Verified 2 days ago
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
Bionomics Limited announced today the publication of its international clinical study involving patients with a form of epilepsy confined to early childhood in the scientific journal, Annals of Neurology. The publication details genes associated with a condition known as Benign Familial Neonatal Infantile Spasms (BFNIS), a condition in which infants experience seizures in the first few months of their life.
Some prostate cancer patients unnecessarily undergo surgery or harsh treatments because science fails to identify the differences between slow-growing and aggressive forms of the disease. Researchers at Case Western Reserve University and Johns Hopkins Medical Institutes are developing technology that allows patients to safely choose to do nothing, opt for relatively mild treatments or take drastic measures.
The twin epidemics of obesity and type 2 diabetes will continue to fuel an explosion in heart failure, already the world's most prevalent chronic cardiovascular disease, according to John McMurray, professor of cardiology at the Western Infirmary, Glasgow, and President of the Heart Failure Association. He reported that around one-third of patients with heart failure have evidence of diabetes, and for them the outlook is very serious. For doctors, he added, effective treatment is "very difficult".
Matrix-Bio, Inc., a diagnostics company that uses metabolite profiling to detect cancer and other diseases, has signed an exclusive global licensing and marketing agreement for metabolomic biomarkers with Quest Diagnostics, the world's leading provider of diagnostic information services. Under the agreement, Quest Diagnostics will have the rights to use the biomarkers for the future, potential development of a clinical lab-developed test to aid in the detection of breast cancer recurrence.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ezechinyerem D Uzosike, MD 2050 Pfingsten Rd, Suite 200, Glenview, IL 60026-1324 Ph: (847) 657-1840 | Dr Ezechinyerem D Uzosike, MD 2050 Pfingsten Rd, Suite 200, Glenview, IL 60026-1324 Ph: (847) 657-1840 |
News Archive
Bionomics Limited announced today the publication of its international clinical study involving patients with a form of epilepsy confined to early childhood in the scientific journal, Annals of Neurology. The publication details genes associated with a condition known as Benign Familial Neonatal Infantile Spasms (BFNIS), a condition in which infants experience seizures in the first few months of their life.
Some prostate cancer patients unnecessarily undergo surgery or harsh treatments because science fails to identify the differences between slow-growing and aggressive forms of the disease. Researchers at Case Western Reserve University and Johns Hopkins Medical Institutes are developing technology that allows patients to safely choose to do nothing, opt for relatively mild treatments or take drastic measures.
The twin epidemics of obesity and type 2 diabetes will continue to fuel an explosion in heart failure, already the world's most prevalent chronic cardiovascular disease, according to John McMurray, professor of cardiology at the Western Infirmary, Glasgow, and President of the Heart Failure Association. He reported that around one-third of patients with heart failure have evidence of diabetes, and for them the outlook is very serious. For doctors, he added, effective treatment is "very difficult".
Matrix-Bio, Inc., a diagnostics company that uses metabolite profiling to detect cancer and other diseases, has signed an exclusive global licensing and marketing agreement for metabolomic biomarkers with Quest Diagnostics, the world's leading provider of diagnostic information services. Under the agreement, Quest Diagnostics will have the rights to use the biomarkers for the future, potential development of a clinical lab-developed test to aid in the detection of breast cancer recurrence.
› Verified 2 days ago
Martin Kovachevich, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2050 Pfingsten Rd, Suite 330, Glenview, IL 60026 Phone: 847-998-4100 Fax: 847-998-8439 | |
Leslie Mendoza Temple, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 Chestnut Ave, Suite A, Glenview, IL 60026 Phone: 847-657-3540 Fax: 847-657-3521 | |
Dr. Deborah Elizabeth Miller, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2050 Pfingsten Rd Ste 200, Glenview, IL 60026 Phone: 847-657-1820 Fax: 847-657-1823 | |
Khaldoun Dalbik, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2050 Pfingsten Rd, Glenview, IL 60026 Phone: 847-657-1810 | |
Rachael Libertin, Family Medicine Medicare: Medicare Enrolled Practice Location: 2050 Pfingsten Rd, Glenview, IL 60026 Phone: 847-657-1812 | |
Esther Francine Vergara, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1255 Milwaukee Ave, Glenview, IL 60025 Phone: 847-294-5490 Fax: 847-294-5496 |